🇺🇸 US Stock Screener ← Switch market ★ Elite Club ⚡ HerAI

United Therapeutics Corporation UTHR R3KPHARMA

Healthcare · Drug Manufacturers - Specialty & Generic · United States
https://www.unither.com
Company Profile ↓
$538.84
+78.72% 1Y
Mkt Cap$23.11B
P/E19.30
P/B3.67
52W High$596.76
52W Low$300.43
Book Value$146.65
EPS (TTM)$27.92

Company Overview

United Therapeutics Corporation engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. It offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Nebulized Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients. It also markets and sells Unituxin (dinutuximab) injection, a monoclonal antibody for high-risk neuroblastoma; and Remunity Pump, which contains a pump and separate controller for Remodulin. In addition, it is involved in developing RemunityPRO Pump and Ralinepag for the treatment of PAH;and Nebulized Tyvaso, for the treatment of idiopathic pulmonary fibrosis, as well as xenografts, which are development-stage organ products. Further, it provides preclinical products, including EVLP/CLES, for lung transplant; UKidney, UHeart, UThymoKidney, a development-stage gene-edited porcine kidneys and hearts for xenotransplantation; ULobe, for allogeneic regenerative medicine; ULung, for autologous regenerative medicine; IVIVA Kidney, for autologous regenerative medicine; miroliver, for allogeneic regenerative medicine; and mirokidney, for allogeneic regenerative medicine. It has licensing and collaboration agreements with DEKA Research & Development Corp. to develop a semi-disposable system for the subcutaneous delivery of treprostinil; MannKind Corporation to develop and license treprostinil inhalation powder and the Dreamboat device; and Arena Pharmaceuticals, Inc. to develop Ralinepag. The company was founded in 1996 and is headquartered in Silver Spring, Maryland.

Why Investors Should Care

Strong Return on Equity

Generates a return on equity of 19.3%, reflecting efficient use of shareholder capital.

Healthy Capital Returns

Return on capital employed stands at 20.4%.

Consistent Profit Growth

Net profit has compounded at 30.2% per year over the last five years.

Steady Revenue Expansion

Revenue has grown at a 15.3% CAGR over the past five years.

Reasonable Valuation

Trades at a P/E of 19.3, below the sector median of 27.6.

Healthy Margins

Maintains a net profit margin of 41.6%.

Recent Developments

  • Dec 2025 Revenue of $3.18B (+10.6% YoY); net profit $1.33B.
  • Trailing 12 Months Year-on-year growth — revenue -1.9%, earnings +13.4%.
  • 5-Year Trend Long-term compounding — revenue CAGR 15.3%, profit CAGR 30.2%.

Growth & Price Performance

Compounded Sales Growth

5 Years:15.33%
1 Year:-1.90%

Compounded Profit Growth

5 Years:30.25%
1 Year:13.40%

Stock Price Performance

1 Year:+78.72%
6 Months:+12.51%
3 Months:-5.33%
1 Month:-2.47%

Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.

Technical Snapshot Mixed
52-Week Range 80% of range
$300.43 $596.76
Trend Signals
  • Price vs 50-DMABelow
  • Price vs 200-DMAAbove
  • RSI (14)54.95 · Neutral
Price Performance
1M-2.47%
3M-5.33%
6M+12.51%
1Y+78.72%
Valuation vs Sector

P/E of 19.30 is below the sector median of 27.57 — relatively cheaper than peers.

Auto-generated from price history and fundamentals; not investment advice.

⚙Ad space

Price Chart

Robinhood TradingView

Fundamental Growth Charts

Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.

PROS

  • Healthy ROCE of 20.4%.
  • Excellent profit margin of 41.6%.
  • Compounding revenue at 15.3% over 5 years.
  • Profit CAGR of 30.2% over 5 years.
  • Generates positive free cash flow.
  • In a confirmed uptrend (50-DMA above 200-DMA).

CONS

No notable concerns flagged.

* The pros and cons are auto-generated from financial metrics.

⚙Ad space

Valuation

Stock P/E
19.30
Industry PE
27.57
Forward P/E
17.87
PEG Ratio
2.22
Book Value
$146.65
Price to Book
3.67
P/S
7.33
EV/EBITDA
13.67
Dividend Yield
0.00%

Growth (CAGR)

Revenue 5Y
15.33%
Profit 5Y
30.25%
Revenue (YoY)
-1.90%
Earnings (YoY)
13.40%

Profitability & Returns

ROCE
20.39%
ROE
19.31%
ROA
11.61%
Profit Margin
41.56%
Op Margin
42.23%
Gross Margin
86.14%
EPS (Latest Qtr)
$7.27
EPS (TTM)
$27.92

Balance Sheet & Liquidity

Debt/Equity
-
Quick Ratio
4.89
Current Ratio
5.73
Debt
$0
Total Assets
$7.22B
Current Assets
-
Working Capital
-

Ownership

Promoter Holding
2.03%
Chg in Prom Hold
-
FII / Inst Holding
100.30%
Chg in FII Hold
-

Financial Snapshot

Enterprise Value
$23.11B
Total Revenue (TTM)
$3.15B
EBITDA
$1.50B
Free Cash Flow
$557.14M
Operating Cash Flow
$1.69B
Shares Outstanding
42.89M
Gross Margin
86.14%
Payout Ratio
0.00%

Peer comparison

Peer companies in the same sector (Healthcare).

#NameCMP $P/E Mkt CapDiv Yld % ROCE %ROE % Rev CAGR 5Y %Profit CAGR 5Y %
1 UTHR United Therapeutics Corporation R3KPHARMA 538.84 19.30 $23.11B 0.00% 20.39% 19.31% 15.33% 30.25%
2 LLY Eli Lilly and Company SPXR3KPHARMA 1,185.71 39.79 $1.06T 0.58% - 102.29% 7.20% 11.41%
3 JNJ Johnson & Johnson SPXR3KPHARMA 259.24 30.11 $624.74B 2.09% 14.88% 25.74% 2.43% 4.76%
4 ABBV AbbVie Inc. SPXR3KPHARMA 246.04 69.50 $434.78B 2.84% 10.47% -129.24% 1.75% -29.06%
5 UNH UnitedHealth Group Incorporated SPXR3KPHARMA 407.08 30.68 $369.69B 2.18% 9.74% 12.18% 10.40% 5.43%
6 MRK Merck & Co., Inc. SPXR3KPHARMA 128.58 102.86 $317.57B 2.65% - 34.70% 5.64% 10.01%
7 AZN AstraZeneca PLC NDXPHARMA 161.42 24.16 $250.34B 1.98% 15.97% 21.96% 9.82% 45.96%
8 AMGN Amgen Inc. NDXSPXR3KPHARMA 410.94 25.51 $221.79B 2.49% 13.95% 91.47% 5.51% 5.55%
9 TMO Thermo Fisher Scientific Inc. SPXR3KPHARMA 594.00 32.00 $219.63B 0.32% 8.14% 13.51% 8.81% 12.95%
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios

Quarterly Results

Figures in USD.

Metric Mar 2015Jun 2015Sep 2015Dec 2015Mar 2016Jun 2016Sep 2016Dec 2016Mar 2017Jun 2017Sep 2017Dec 2017Mar 2018Jun 2018Sep 2018Dec 2018Mar 2019Jun 2019Sep 2019Dec 2019Mar 2020Jun 2020Sep 2020Mar 2021Jun 2021Sep 2021Mar 2022Jun 2022Sep 2022Mar 2023Jun 2023Sep 2023Mar 2024Jun 2024Sep 2024Mar 2025Jun 2025Sep 2025Mar 2026Jun 2026
Revenue --------370.50M444.60M445.50M-389.20M444.50M412.70M-362.60M373.60M401.50M-356.30M362.00M380.10M379.10M446.50M444.70M461.90M466.90M516.00M506.90M596.50M609.40M677.70M714.90M748.90M794.40M798.60M799.50M781.50M783.30M
Gross Profit 306.70M331.20M379.30M379.60M368.30M392.60M384.60M380.60M356.20M425.70M426.00M411.70M336.00M382.80M360.80M349.50M333.50M346.90M368.50M282.30M---356.10M409.30M417.00M436.00M437.20M478.80M454.60M532.40M539.30M604.80M637.10M665.80M701.90M711.00M698.60M648.10M683.80M
Operating Income -14.80M171.80M387.00M-363.70M285.20M238.60M-263.60M88.50M323.80M-306.90M217.40M149.60M--655.90M221.40M183.40M-166.70M140.50M221.10M-64.80M222.20M228.70M288.00M201.80M314.30M284.40M313.40M327.00M356.30M319.90M343.10M382.80M364.50M388.50M325.80M330.80M
Net Income -----------------205.10M132.40M-137.70M107.10M171.20M28.30M172.60M162.70M239.90M116.00M239.30M240.90M259.20M267.60M306.60M278.10M309.10M322.20M309.50M338.70M274.90M333.00M
Diluted EPS -0.361.919.242.104.844.393.502.433.89-1.256.270.435.573.982.421.48-11.324.663.011.203.122.413.840.613.653.425.032.414.914.865.245.386.175.856.396.636.417.165.827.27
R&D Expense 110.21M49.41M9.60M---45.90M-----35.70M82.30M101.10M-897.40M85.90M85.70M-73.20M89.70M68.70M303.70M74.30M79.20M69.00M93.90M66.10M82.90M89.00M84.70M104.10M139.60M103.50M149.00M134.00M127.50M138.20M146.30M

Profit & Loss (Annual)

Figures in USD.

Metric Dec 2008Dec 2009Dec 2010Dec 2011Dec 2012Dec 2013Dec 2014Dec 2015Dec 2016Dec 2017Dec 2018Dec 2019Dec 2020Dec 2021Dec 2022Dec 2023Dec 2024Dec 2025
Revenue 281.50M358.88M592.90M743.18M916.08M1.12B1.29B1.47B1.60B1.73B1.63B1.45B1.48B1.69B1.94B2.33B2.88B3.18B
Gross Profit -316.77M524.03M652.19M786.83M975.82M1.15B----1.33B1.38B1.56B1.78B2.07B2.57B2.80B
Operating Income -82.06M25.76M171.31M317.78M421.65M292.50M538.80M699.00M1.06B814.90M805.40M-187.60M593.60M555.90M979.70M1.18B1.38B1.49B
Net Income -19.46M105.92M217.87M304.44M174.56M340.10M651.60M713.70M417.90M589.20M-104.50M514.80M475.80M727.30M984.80M1.20B1.33B
Diluted EPS -1.080.351.783.675.713.286.2812.7215.259.3113.39-2.3911.5410.0615.0019.8124.6427.86
R&D Expense 239.18M120.37M165.31M180.01M173.39M299.35M242.50M245.10M147.60M264.60M357.90M1.18B357.70M540.10M322.90M408.00M481.00M550.00M

Balance Sheet (Annual)

Figures in USD.

Metric Dec 2007Dec 2008Dec 2009Dec 2010Dec 2011Dec 2012Dec 2013Dec 2014Dec 2015Dec 2016Dec 2017Dec 2018Dec 2019Dec 2020Dec 2021Dec 2022Dec 2023Dec 2024Dec 2025
Total Assets --1.05B1.43B1.52B1.63B2.09B1.88B2.18B2.33B2.88B3.40B3.91B4.62B5.17B6.04B7.17B7.36B7.88B
Total Equity 352.13M555.33M653.01M883.89M948.49M1.08B1.26B1.24B1.59B1.85B2.10B2.79B2.78B3.40B3.96B4.80B5.98B6.44B7.10B
Cash & Equivalents 139.32M129.45M100.35M252.16M168.04M159.40M284.30M397.70M831.80M1.02B705.10M669.20M738.40M738.70M894.80M961.20M1.21B1.70B1.56B
Total Liabilities --387.65M536.87M558.71M531.73M783.26M618.84M584.70M463.40M758.40M593.20M1.13B1.22B1.21B1.25B1.18B920.00M783.80M
Current Liabilities --330.19M428.69M212.58M176.75M687.67M504.31M440.70M332.50M444.70M276.60M463.00M323.30M305.40M343.20M804.40M738.10M560.60M

Cash Flows (Annual)

Figures in USD.

Metric Dec 2008Dec 2009Dec 2010Dec 2011Dec 2012Dec 2013Dec 2014Dec 2015Dec 2016Dec 2017Dec 2018Dec 2019Dec 2020Dec 2021Dec 2022Dec 2023Dec 2024Dec 2025
Operating Cash Flow -40.43M99.72M211.53M250.19M323.63M--382.80M643.60M474.20M778.40M-206.60M755.70M598.20M802.50M978.00M1.33B1.56B
Investing Cash Flow -181.24M-162.62M-209.24M-121.33M-163.36M--503.60M48.30M-835.60M-820.60M-335.40M-738.50M-486.90M-811.50M-719.60M417.20M-551.30M
Financing Cash Flow 213.03M36.48M146.76M-218.08M-169.14M---447.00M-497.70M43.30M6.30M611.20M-16.90M44.80M75.40M-11.90M-1.25B-1.15B
Capital Expenditure -124.42M-95.40M-18.64M-35.98M-111.91M-31.91M-47.40M-49.80M-38.00M-86.30M-184.40M-83.70M-59.30M-120.80M-138.80M-230.40M-246.50M-520.50M
Free Cash Flow -164.84M4.32M192.89M214.22M211.72M--333.00M605.60M387.90M594.00M-290.30M696.40M477.40M663.70M747.60M1.08B1.04B
Share Buybacks ---212.00M188.00M42.44M483.10M394.50M500.00M250.00M----001.00B1.00B

Ratios (Annual)

Figures in %.

Metric Dec 2008Dec 2009Dec 2010Dec 2011Dec 2012Dec 2013Dec 2014Dec 2015Dec 2016Dec 2017Dec 2018Dec 2019Dec 2020Dec 2021Dec 2022Dec 2023Dec 2024Dec 2025
Gross Margin % -88.3%88.4%87.8%85.9%87.4%89.5%----91.9%92.7%92.7%92.2%88.9%89.2%87.9%
Operating Margin % -29.1%7.2%28.9%42.8%46.0%26.2%41.8%47.7%66.4%47.2%49.5%-12.9%40.0%33.0%50.6%50.9%47.9%46.9%
Net Margin % -5.4%17.9%29.3%33.2%15.6%26.4%44.5%44.6%24.2%36.2%-7.2%34.7%28.2%37.6%42.3%41.5%41.9%
ROE % -3.0%12.0%23.0%28.1%13.9%27.4%41.0%38.6%19.9%21.1%-3.8%15.2%12.0%15.2%16.5%18.5%18.8%
ROCE % -3.6%17.1%24.3%29.1%20.9%39.0%40.1%53.3%33.5%25.8%-5.4%13.8%11.4%17.2%18.6%20.8%20.4%

Shareholding Pattern

Insiders
2.03%
Institutions
100.30%
Public Float
102.38%

Top Institutional Holders

#Holder% HeldSharesValue
1 Blackrock Inc. 12.59% 5.40M $2.91B
2 Avoro Capital Advisors LLC 6.13% 2.63M $1.42B
3 Wellington Management Group, LLP 5.28% 2.26M $1.22B
4 Vanguard Portfolio Management LLC 4.67% 2.00M $1.08B
5 Vanguard Capital Management LLC 4.56% 1.96M $1.05B
6 State Street Corporation 4.30% 1.84M $993.60M
7 Renaissance Technologies, LLC 4.17% 1.79M $962.92M
8 Geode Capital Management, LLC 2.87% 1.23M $664.41M
9 Janus Henderson Group PLC 2.02% 866.93K $467.14M
10 AQR Capital Management, LLC 1.93% 826.23K $445.20M

Analyst View

Loading analyst coverage…

Latest News

Recent headlines for UTHR

No recent headlines available.

UTHR — Frequently Asked Questions

What is the current share price of United Therapeutics Corporation (UTHR)?

As of 2026-08-07 20:37 PDT, United Therapeutics Corporation (UTHR) trades at $538.84 on NasdaqGS. Its 52-week range is $300.43 to $596.76.

What is the market capitalisation of UTHR?

United Therapeutics Corporation (UTHR) has a market capitalisation of $23.11B on NasdaqGS.

What is the P/E ratio of UTHR?

UTHR trades at a trailing price-to-earnings (P/E) ratio of 19.30. The industry average P/E is 27.57. Its price-to-book (P/B) ratio is 3.67.

What is the return on equity (ROE) of UTHR?

UTHR has a return on equity (ROE) of 19.31%. Its return on capital employed (ROCE) is 20.39%.

Is UTHR a good stock to buy?

This page provides a data-driven analysis of United Therapeutics Corporation (UTHR), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.

Explore More

📊 Healthcare Sector 🔍 All Stock Screens 📈 Technical Screens 💰 Fundamental Screens 🔄 Swing Trading Setups 📐 Chart Patterns 📅 Earnings Calendar 📋 All USA Stocks
⚙Ad space